Bright Biologics attended the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting on November 8-10, 2024, in Houston, TX.
SITC is the world's largest cancer immunotherapy conference, where leading scientists from academia and industry gather to present cutting-edge research, participate in oral and poster abstract sessions, and engage in valuable networking opportunities. During this meeting, CEO Dr. Ming Yang presented two posters that attracted significant attention. He showcased the potential best-in-class anti-PD-L1 × anti-VEGF bispecific antibody (BsAb) in the rapidly evolving field of immuno-oncology, highlighting two major deals recently announced. Additionally, Dr. Yang presented the anti-Trop2 × anti-Her2-ADC, a promising first-in-class bispecific antibody-drug conjugate (ADC) for cancer patients.
